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Vaccine hesitancy is a complex public health issue referring to concerns about safety, efficacy, or
need for vaccination. Using pneumococcal vaccination, which is recommend in anti-CD20–
treated multiple sclerosis (MS) patients, as a model, we assessed vaccination behavior in
patients with MS to prepare for the upcoming SARS-CoV-2 vaccination challenge.
Methods
By a medical chart review, we retrospectively identified patients with MS treated with ocreli-
zumab at the University Hospital Bern in 2018–2020. Pneumococcal vaccination was discussed
with the patients during clinical visits and highlighted in the after-visit summary addressed to
the general practitioner before ocrelizumab initiation as part of our clinical standard of care.
Results
Pneumococcal vaccination was performed in 71/121 (58.7%) of patients, and 50/121 (41.3%)
patients were not vaccinated. Patients who did not get a pneumococcal vaccination were
younger (no vaccination vs vaccination; mean [95%CI] 40.1 [36.1–44.1] vs 45.4 [41.9–48.8], p
= 0.028) and had more frequently a relapsing remitting disease course (no vaccination vs
vaccination, n [%]; 43/50 [86.0%] vs 49/71 [69.0%], p = 0.031). Furthermore, patients who
did not get vaccination had more frequently a history of comorbid psychiatric disorder (no
vaccination vs vaccination, n (%); 12/50 [24.0] vs 7/71 [9.8], p = 0.035).
Conclusion
Our study demonstrated that in our single-center cohort, 41.3% of patients with MS do not get
the recommended pneumococcal vaccination. Future research should focus on vaccine hesitancy
in the vulnerable cohort of patients with MS to improve the safety of MS immunotherapies.
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Vaccine hesitancy is a complex public health issue referring to
concerns about the safety, efficacy, or need for vaccination.1
Each year, Streptococcus pneumoniae is estimated to cause
more than 1,000 serious infections in Switzerland.2 Patients
with multiple sclerosis (MS) treated with ocrelizumab (OCR,
Ocrevus, Roche, Basel, Switzerland) are at risk of S. pneu-
moniae infections. The Swiss Federal Office of Public Health
(FOPH) recommends pneumococcal vaccination in patients
treated with immunosuppressants including OCR.3 Using
pneumococcal vaccination as a model, we aimed to assess
vaccination behavior in patients with MS to prepare for the
upcoming SARS-CoV-2 vaccination challenge.
Methods
By amedical chart review, we retrospectively identified patients
with MS treated with OCR at the University Hospital Bern in
2018–2020 leading to a cohort of 166 patients. Of 166 patients,
45 patients were excluded because of missing clinical in-
formation regarding vaccination status because of the retro-
spective nature of our study, resulting in a cohort of 121
patients (table e-1, links.lww.com/NXI/A466). Pneumococcal
vaccination was recommended as indicated per FOPH guide-
lines,3 discussed with the patients during clinical visits, and
highlighted in the after-visit summary addressed to the general
practitioner before OCR initiation as part of our clinical stan-
dard of care.
The following variables were extracted from medical re-
cords: age, sex, Expanded Disability Status Scale (EDSS),
MS diagnosis, type of MS, disease modifying therapies
before switching, time of vaccination, reason for miss-
ing vaccination, clinical relapse before OCR start, MRI
activity—defined as gadolinium-enhancing lesion and/
or new/enlarging T2 lesion—1 year before/after start of
therapy/vaccination, and concomitant psychiatric disor-
ders. Continuous variables are presented as mean and 95%
CIs, whereas categorical variables are reported as fre-
quencies. Continuous variables are compared using Mann-
Whitney U and Wilcoxon signed rank tests and categorical
variables with the χ2 test.
Standard Protocol Approvals, Registrations,
and Patient Consents
The study was approved by the Cantonal Ethics Committee
(KEK-BE #2017-01369).
Data Availability
Anonymized source data are available upon reasonable re-
quest via the corresponding author.
Results
Patients were 43.2 years old (mean, 95% CI 40.6–45.8),
predominantly female 75/121 (62.0%), and had a moderate
degree of disability (mean EDSS (95% CI): 3.1 (2.8–3.4);
table 1).
Pneumococcal vaccinationwas performed in 71/121 (58.7%) of
patients in mean 4.0 weeks before first dose of OCR (95% CI
0.2–7.8) with a range of 46.44 weeks before and 68.53 weeks
after first dose OCR. In total, 50/121 (41.3%) patients were not
vaccinated. In these 50 patients, the reasons for lack of vacci-
nation were as follows: lack of adherence to vaccination rec-
ommendations (n = 30), MS disease activity (n = 11), general
vaccination recommendation (not specifically for pneumococ-
cal vaccine) in after-visit summary addressed to the general
practitioner (n = 8), and unexpected pregnancy (n = 1).
Patients who did not get a pneumococcal vaccination were
younger (no vaccination vs vaccination; mean [95% CI] 40.1
[36.1–44.1] vs 45.4 [41.9–48.8], p = 0.028) and had more
frequently a relapsing remitting (RR) disease course (no
vaccination vs vaccination, n [%]; 43/50 [86.0%] vs 49/71
[69.0%], p = 0.031). Furthermore, patients who did not get a
pneumococcal vaccination had more frequently a history of
comorbid psychiatric disorder (no vaccination vs vaccination,
n [%]; 12/50 [24.0] vs 7/71 [9.8], p = 0.035) including
depression (n = 8), psychosis (n = 2), history of drug abuse (n
= 1), and borderline personality disorder (n = 1) in those
without vaccination.
MS immunotherapies before initiation of OCR had an impact
on vaccination behavior: untreated patients with MS were
vaccinated more frequently compared with treated patients
with MS (14/50 [28.0%] vs 34/71 [47.8%], p = 0.028).
Clinical and MRI disease activity within 12 months before
OCR did not differ between patients with and without vac-
cination. Initiation of OCR resulted in a reduction of disease
activity in both patient cohorts. Because date of vaccination
differs from date of first OCR treatment, we also investigated
in the subgroup of vaccinated MS patients for clinical and
radiologic disease activity within 1 year before and after vac-
cination, which demonstrates a similar reduction of disease
activity after OCR compared with the whole cohort (table 1).
Discussion
Our study demonstrated that in our single-center cohort,
41.3% of patients with MS do not get the recommended
pneumococcal vaccination before initiation of OCR. Those
Glossary
CAM = complementary and alternative medicine; EDSS = Expanded Disability Status Scale; FOPH = Federal Office of Public
Health; MS = multiple sclerosis; OCR = ocrelizumab.
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Table 1 Patient Characteristics Concerning Pneumococcal Vaccination Status
Variable All patients (n = 121)
Female, n (%) 75/121 (62.0)
Age (y), mean (95% CI) 43.2 (40.6–45.8)
MS type, n (%)
RRMS 92/121 (76.0)
PPMS 29/121 (24.0)
EDSS, mean (95% CI) 3.1 (2.8–3.4)
Disease duration (y), mean (95% CI) 6.5 (5.3–7.7)
DMT before switch
No medication 48/121 (39.7)
First-line treatment 26/121 (21.5)
Second-line treatment 47/121 (38.8)
Vaccinated patients 71/121 (58.7)
Time between vaccination and first OCR dose (wk), mean (95% CI) 4.0 (0.2–7.8)
Reason for being unvaccinated
Lack of adherence to vaccination recommendations 30/50 (60.0)
Only general vaccination recommendation 8/50 (14.0)
Disease activity 11/50 (22.0)
Pregnancy 1/50 (2.0)
Variable With vaccination (n = 71) Without vaccination (n = 50) p Value
Female, n (%) 43/71 (60.6) 32/50 (64.0) 0.701
Age (y), mean (95% CI) 45.4 (41.9–48.8) 40.1 (36.1–44.1) 0.028
EDSS, mean (95% CI) 3.1 (2.7–3.5) 3.0 (2.5–3.5) 0.793
RRMS, n (%) 49/71 (69.0) 43/50 (86.0) 0.031
Disease duration (y), mean (95% CI) 6.1 (4.4–6.8) 6.8 (5.0–8.5) 0.916
No medication, n (%) 34/71 (47.9) 14/50 (28.0) 0.028
First-line treatment, n (%) 12/37 (32.4) 14/36 (38.9) 0.565
Second-line treatment, n (%) 25/37 (67.6) 22/36 (61.1) 0.565
Psychiatric disorder, n (%) 7/71 (9.8) 12/50 (24.0) 0.035
Clinical relapse 12 mo before OCR start, n (%) 19/71 (26.8) 16/50 (32.0) 0.531
Clinical relapse 12 mo after OCR start, n (%) 0/71 0/50 1.0
MRI activity 12 mo before OCR start, n (%) 30/62 (48.4) 26/45 (57.8) 0.337
MRI activity 12 mo after OCR start, n (%) 0/49 1/32 0.213
Variable 1 year before OCR (n = 121) 1 year after OCR (n = 121) p Value
Clinical activity, n (%) 35/121 (28.9) 0/121 (0) <0.001
MRI activity, n (%) 56/107 (52.3) 1/81 (0) <0.001
Variable 1 year before vaccination (n = 71) 1 year after vaccination (n = 71) p Value
Clinical activity, n (%) 19/71 (26.8) 0/71 (0) <0.001
MRI activity, n (%) 30/62 (48.4) 0/49 (0 = ) <0.001
Abbreviations: DMT = disease modifying therapy; EDSS = Expanded Disability Status Scale; n.a = not applicable; OCR = ocrelizumab; PPMS = primary
progressive multiple sclerosis; RRMS = relapsing remitting multiple sclerosis.
MRI activity was defined as the presence of gadolinium-enhancing lesion/s and/or new or enlarging T2 lesion/s on cMRI.
Statistics: Continuous variables are presented as mean and 95% CIs, whereas categorical variables are reported as frequencies. Continuous variables are
compared usingMann-Whitney U andWilcoxon signed rank tests and categorical variables with the χ2 test. Significant p values are highlighted in bold letters.
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patients were younger and had more frequently an RR disease
course and a psychiatric comorbidity. This finding may be
related to the behavior of young people toward vaccination.
Often, young people argue that the corresponding diseases do
not affect them and that the risk is mainly in older people.
Moreover, patients with use of disease-modifying treatments
before initiation of OCR, which should not influence the de-
cision to vaccinate against S. pneumoniae, did get vaccinations
less frequently compared with untreated patients. MS disease
activation after pneumococcal vaccination could not be ob-
served neither in clinical relapses nor in MRI disease activity.
These findings are crucial because the fear of disease activity is a
main argument against vaccination in people with MS.4 This
study showed that vaccine hesitancy remains a widespread
problem in our monocentric cohort. Vaccine hesitancy is de-
fined as the delay in acceptance or refusal of vaccination despite
the availability of vaccination services.5 Vaccine hesitancy is an
individual behavior influenced by a range of factors, such as
knowledge or experiences in the past. The absence of awareness
about “who and why” one should be vaccinated and self-
estimated (in)sufficiency of information about vaccination is
frequently associated with vaccination decisions.6 Perceived
importance of vaccination is an individual determinant of vac-
cine adherence. Individuals who refuse or are hesitant regarding
vaccination often have an own worldview regarding health (e.g.,
importance of natural immunity).7 Similarly, the increasing
popularity of complementary and alternative medicine (CAM)
plays an important role in the vaccination skepticism of the
population. In fact, refusal of vaccination is significantly more
frequent among CAM-users than among nonusers. Patients
who consulted physicians practicing herbal medicine, anthro-
posophical medicine, or homeopathy reported the highest fre-
quencies of vaccination refusal.8 In addition, experiences with
vaccinations in the past can influence future decision-making
regarding vaccination. Vaccine hesitancy can also be the result of
broader influences and should always be looked at in the his-
torical, political, and sociocultural context in which vaccination
is discussed. The trust placed in the healthcare system, in the
doctors who recommend and administer vaccines, and in the
different types of vaccine information conveyed by the media
plays an important role in the decision to be vaccinated.9 Un-
fortunately, vaccine misinformation on major social media
companies is a common problem, and the companies are facing
wide criticism for failing to deal with vaccine misinformation on
their platforms. Especially in the light of the newly available
COVID-19 vaccine, misinformation on social media is un-
doubtedly going to pose a serious barrier to uptake.10 The
Strategic Advisory Group of Experts on ImmunizationWorking
Group discussed that poor communication of healthcare pro-
fessionals plays an important role in the vaccine hesitancy.
When communication of healthcare professionals is poor or
inadequate, it can negatively influence vaccination uptake and
contribute to vaccine hesitancy.5 Therefore, clear and targeted
education, also taking into account social media, about vacci-
nation is imperative. Obviously, we cannot extrapolate these
data concerning pneumococcal vaccination without further ado
on the now available COVID-19 vaccination. However, our
short retrospective observation with all limitations inherent of
the design highlights the fact that physicians caring for people
with MS should proactively initiate vaccination discussions with
their patients and follow up on the execution of the recom-
mendation. Further studies of vaccination behavior in patients
with MS are warranted, especially in the light of the current
pandemic.
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